Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Task-related and person-related variables influence the effect of low back pain on anticipatory postural adjustments.

Jacobs JV, Lyman CA, Hitt JR, Henry SM.

Hum Mov Sci. 2017 Aug;54:210-219. doi: 10.1016/j.humov.2017.05.007. Epub 2017 May 17.

2.

Genome-wide transcriptional profiling of the cyclic AMP-dependent signaling pathway during morphogenic transitions of Candida albicans.

Bahn YS, Molenda M, Staab JF, Lyman CA, Gordon LJ, Sundstrom P.

Eukaryot Cell. 2007 Dec;6(12):2376-90. Epub 2007 Oct 19.

3.

Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.

Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ.

J Infect Dis. 2007 Feb 1;195(3):455-66. Epub 2006 Dec 21.

PMID:
17205486
4.

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, Alfaro RM, Schaufele RL, Sein T, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2006 Oct;50(10):3418-23.

5.

Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus.

Cortez KJ, Lyman CA, Kottilil S, Kim HS, Roilides E, Yang J, Fullmer B, Lempicki R, Walsh TJ.

Infect Immun. 2006 Apr;74(4):2353-65.

6.
7.

Control, immunoregulation, and expression of innate pulmonary host defenses against Aspergillus fumigatus.

Walsh TJ, Roilides E, Cortez K, Kottilil S, Bailey J, Lyman CA.

Med Mycol. 2005 May;43 Suppl 1:S165-72. Review.

PMID:
16114132
8.
9.

Effects of interleukin-15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp.

Winn RM, Gil-Lamaignere C, Roilides E, Simitsopoulou M, Lyman CA, Maloukou A, Walsh TJ.

Cytokine. 2005 Jul 7;31(1):1-8.

PMID:
15935692
10.

Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans.

Kim HS, Choi EH, Khan J, Roilides E, Francesconi A, Kasai M, Sein T, Schaufele RL, Sakurai K, Son CG, Greer BT, Chanock S, Lyman CA, Walsh TJ.

Infect Immun. 2005 Jun;73(6):3714-24.

11.

Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Petraitiene R, Petraitis V, Lyman CA, Groll AH, Mickiene D, Peter J, Bacher J, Roussillon K, Hemmings M, Armstrong D, Avila NA, Walsh TJ.

Antimicrob Agents Chemother. 2004 Apr;48(4):1188-96.

12.

Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injury.

Gil-Lamaignere C, Roilides E, Lyman CA, Simitsopoulou M, Stergiopoulou T, Maloukou A, Walsh TJ.

Infect Immun. 2003 Nov;71(11):6472-8.

13.

Selective effects of interleukin (IL)-15 on antifungal activity and IL-8 release by polymorphonuclear leukocytes in response to hyphae of Aspergillus species.

Winn RM, Gil-Lamaignere C, Roilides E, Simitsopoulou M, Lyman CA, Maloukou A, Walsh TJ.

J Infect Dis. 2003 Aug 15;188(4):585-90. Epub 2003 Jul 29.

PMID:
12898448
14.

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi MG, Lyman CA.

J Infect Dis. 2003 Jul 15;188(2):305-19. Epub 2003 Jul 9.

PMID:
12854088
15.

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein T, Groll AH, Bacher J, Avila NA, Walsh TJ.

J Infect Dis. 2003 Jun 15;187(12):1834-43. Epub 2003 Jun 4.

PMID:
12792859
16.

Immunomodulation of invasive fungal infections.

Roilides E, Lyman CA, Panagopoulou P, Chanock S.

Infect Dis Clin North Am. 2003 Mar;17(1):193-219. Review.

PMID:
12751266
17.

Macrophage colony-stimulating factor enhances phagocytosis and oxidative burst of mononuclear phagocytes against Penicillium marneffei conidia.

Roilides E, Lyman CA, Sein T, Petraitiene R, Walsh TJ.

FEMS Immunol Med Microbiol. 2003 May 15;36(1-2):19-26.

18.

Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.

Roilides E, Lyman CA, Filioti J, Akpogheneta O, Sein T, Lamaignere CG, Petraitiene R, Walsh TJ.

Antimicrob Agents Chemother. 2002 Jun;46(6):1974-6.

19.

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ.

Antimicrob Agents Chemother. 2002 Jun;46(6):1857-69.

20.

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ.

Antimicrob Agents Chemother. 2001 Oct;45(10):2845-55.

21.

Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus.

Gonzalez CE, Lyman CA, Lee S, Del Guercio C, Roilides E, Bacher J, Gehrt A, Feuerstein E, Tsokos M, Walsh TJ.

Cytokine. 2001 Jul 21;15(2):87-95.

PMID:
11500084
22.

Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ.

Antimicrob Agents Chemother. 2001 Feb;45(2):471-9.

23.

Antimicrobial peptides as potential new antifungals.

Müller FM, Lyman CA, Walsh TJ.

Mycoses. 1999;42 Suppl 2:77-82. Review.

PMID:
10865909
24.

Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Walsh TJ, Gonzalez CE, Piscitelli S, Bacher JD, Peter J, Torres R, Shetti D, Katsov V, Kligys K, Lyman CA.

J Clin Microbiol. 2000 Jun;38(6):2369-73.

25.
26.

Antimicrobial peptides as potential new antifungals.

Müller FC, Lyman CA, Walsh TJ.

Mycoses. 1999 Dec;42 Suppl 2:77-82. doi: 10.1111/j.1439-0507.1999.tb00018.x.

PMID:
29265611
27.
28.

Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.

Petraitiene R, Petraitis V, Groll AH, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 1999 Sep;43(9):2148-55.

29.

Adherence of Candida albicans to bladder mucosa: development and application of a tissue explant assay.

Lyman CA, Navarro E, Garrett KF, Roberts DD, Pizzo PA, Walsh TJ.

Mycoses. 1999;42(4):255-9.

PMID:
10424092
30.

Increased adherence of fluconazole-resistant isolates of Candida species to explanted esophageal mucosa.

Lyman CA, Garrett KF, Peter J, Gonzalez C, Walsh TJ.

Eur J Clin Microbiol Infect Dis. 1999 Mar;18(3):213-6.

PMID:
10357058
31.

Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans.

Vázquez N, Walsh TJ, Friedman D, Chanock SJ, Lyman CA.

Infect Immun. 1998 Jan;66(1):145-50.

32.

Specific induction of fibronectin binding activity by hemoglobin in Candida albicans grown in defined media.

Yan S, Nègre E, Cashel JA, Guo N, Lyman CA, Walsh TJ, Roberts DD.

Infect Immun. 1996 Aug;64(8):2930-5.

33.

Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens.

Roilides E, Lyman CA, Mertins SD, Cole DJ, Venzon D, Pizzo PA, Chanock SJ, Walsh TJ.

Cytokine. 1996 Jan;8(1):42-8.

PMID:
8742065
34.

Invasive fungal infections in children: recent advances in diagnosis and treatment.

Walsh TJ, Gonzalez C, Lyman CA, Chanock SJ, Pizzo PA.

Adv Pediatr Infect Dis. 1996;11:187-290. Review. No abstract available.

PMID:
8718464
35.

New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases.

Walsh TJ, Lyman CA.

Cancer Treat Res. 1995;79:113-48. Review. No abstract available.

PMID:
8746652
37.
38.
39.

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis.

Allende MC, Lee JW, Francis P, Garrett K, Dollenberg H, Berenguer J, Lyman CA, Pizzo PA, Walsh TJ.

Antimicrob Agents Chemother. 1994 Mar;38(3):518-22.

40.
41.
44.
45.

Effects of recombinant human granulocyte-macrophage colony-stimulating factor on intracellular pH in mature granulocytes.

Sullivan R, Griffin JD, Wright J, Melnick DA, Leavitt JL, Fredette JP, Horne JH Jr, Lyman CA, Lazzari KG, Simons ER.

Blood. 1988 Nov;72(5):1665-73.

PMID:
2846087
46.
47.

Cytosolic calcium changes in individual neutrophils stimulated by opsonized and unopsonized Candida albicans hyphae.

Levitz SM, Lyman CA, Murata T, Sullivan JA, Mandell GL, Diamond RD.

Infect Immun. 1987 Nov;55(11):2783-8.

48.
49.

Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice.

Lyman CA, Sugar AM, Diamond RD.

Antimicrob Agents Chemother. 1986 Jan;29(1):161-2.

50.

Proteolytic activity of Candida albicans and other yeasts.

Schreiber B, Lyman CA, Gurevich J, Needham CA.

Diagn Microbiol Infect Dis. 1985 Jan;3(1):1-5.

PMID:
3881210

Supplemental Content

Loading ...
Support Center